pre-IPO PHARMA

COMPANY OVERVIEW

Elucida Oncology, Inc., is a biotechnology company pioneering the next frontier in targeted cancer therapy with its first-in-class, ultra-small C’Dot drug delivery platform. The company’s C’Dot-Drug-Conjugates, or CDCs, are novel drug candidates designed to substantially increase the concentration of highly potent drugs in difficult to treat tumors with minimal systemic exposure due to their unique Target or Clear™ properties. CDCs enable precise tumor targeting and deep tumor penetration as demonstrated in preclinical studies, resulting in enhanced tumor reduction with reduced off-target toxicity, thereby potentially addressing the limitations of antibody-drug-conjugates (ADCs) and more traditional drug carriers.


LOCATION

  • Monmouth Junction, NJ, USA

  • THERAPEUTIC AREAS

  • Oncology

  • WEBSITE

    https://www.elucidaoncology.com/


    CAREER WEBSITE

    https://www.elucidaoncology.com/careers


    SOCIAL MEDIA


    INVESTORS



    PRESS RELEASES


    Apr 4, 2022

    Elucida Oncology’s Lead Clinical Candidate ELU001 to Be Featured in Two Abstracts at the American Association for Cancer Research Annual Meeting


    Mar 3, 2022

    Elucida Oncology to Present at Two Upcoming Scientific Conferences


    Jan 5, 2022

    Elucida Oncology Provides Corporate Update and Outlines Key Upcoming Milestones


    Jan 5, 2022

    Elucida Oncology to Present at Two Upcoming Investor Conferences


    Jan 5, 2022

    Elucida Oncology to Present at Two Upcoming Investor Conferences


    For More Press Releases


    Google Analytics Alternative